2 February 2012 - Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) and Takeda Pharmaceuticals USA Inc, a subsidiary of Japan's Takeda Pharmaceuticals (TYO:4502), said on Thursday that lubiprostone achieved the primary endpoint in a Phase III clinical study for the treatment of opioid-induced bowel dys...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up